CN104524149A - 一种防治急性肾炎的药物组合物及其应用 - Google Patents
一种防治急性肾炎的药物组合物及其应用 Download PDFInfo
- Publication number
- CN104524149A CN104524149A CN201410809891.5A CN201410809891A CN104524149A CN 104524149 A CN104524149 A CN 104524149A CN 201410809891 A CN201410809891 A CN 201410809891A CN 104524149 A CN104524149 A CN 104524149A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- rhizoma
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- 201000008383 nephritis Diseases 0.000 title claims abstract description 53
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000010231 banlangen Substances 0.000 claims abstract description 22
- 241000628997 Flos Species 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- -1 decoction Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 2
- 241000123069 Ocyurus chrysurus Species 0.000 claims 7
- 241001415959 Grus japonensis Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 61
- 230000000694 effects Effects 0.000 abstract description 32
- 229940079593 drug Drugs 0.000 abstract description 12
- 244000296102 Selinum monnieri Species 0.000 abstract description 4
- 235000019084 Selinum monnieri Nutrition 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 241001278836 Agrimonia pilosa Species 0.000 abstract description 2
- 244000167230 Lonicera japonica Species 0.000 abstract description 2
- 235000017617 Lonicera japonica Nutrition 0.000 abstract description 2
- 240000009235 Rubia cordifolia Species 0.000 abstract description 2
- 241000292546 Taraxacum mongolicum Species 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 2
- 235000000641 Agrimonia pilosa Nutrition 0.000 abstract 1
- 241000722953 Akebia Species 0.000 abstract 1
- 241000605447 Anemarrhena Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000931705 Cicada Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000737241 Cocos Species 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 abstract 1
- 241001369613 Stephania tetrandra Species 0.000 abstract 1
- 229930191283 anemarrhena Natural products 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 description 33
- 208000002193 Pain Diseases 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 210000003734 kidney Anatomy 0.000 description 24
- 230000036407 pain Effects 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 208000004880 Polyuria Diseases 0.000 description 15
- 230000035619 diuresis Effects 0.000 description 15
- 241001103643 Rubia Species 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 206010030302 Oliguria Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 208000003251 Pruritus Diseases 0.000 description 11
- 208000006750 hematuria Diseases 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 206010010904 Convulsion Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 239000012567 medical material Substances 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000003026 hypopharynx Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000025747 Rheumatic disease Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000000552 rheumatic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241000447727 Scabies Species 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 210000004706 scrotum Anatomy 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000723281 Ephedra equisetina Species 0.000 description 1
- 241000723237 Ephedra intermedia Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 241000218670 Ephedraceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000100289 Lonicera confusa Species 0.000 description 1
- 241000173699 Lonicera dasystyla Species 0.000 description 1
- 241001170080 Lonicera hypoglauca Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 240000005498 Setaria italica Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 201000002014 Suppurative Otitis Media Diseases 0.000 description 1
- 241001058321 Taraxacum sinicum Species 0.000 description 1
- 229940121792 Thiazide diuretic Drugs 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- VDIQGOWLVYFDOU-UHFFFAOYSA-H [Ca+]O.[Ca+]O.[Ca+]O.[O-]P([O-])([O-])=O Chemical compound [Ca+]O.[Ca+]O.[Ca+]O.[O-]P([O-])([O-])=O VDIQGOWLVYFDOU-UHFFFAOYSA-H 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003535 nephritogenic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 235000002252 panizo Nutrition 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- SFEUTIOWNUGQMZ-ZHLOSDGBSA-N taraxasterol acetate Chemical compound C([C@@]12C)C[C@H](OC(C)=O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C SFEUTIOWNUGQMZ-ZHLOSDGBSA-N 0.000 description 1
- BKUSDHRTBIFINS-UHFFFAOYSA-N taraxasteryl acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4CCC5(C)CCC(C)(C)CC5C4(C)CCC23)C1(C)C BKUSDHRTBIFINS-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种防治急性肾炎的药物组合物,主要由麻黄、金银花、蒲公英、茜根、仙鹤草、蝉蜕、重楼、夏枯草、泽泻、蛇床子、川芎、白芷、白芍、大蓟、桂枝、木通、知母、煅龙骨、防己、鹿角、山茱萸、茯苓皮、板蓝根组成,其作用靶点众多,有效地解决了急性肾炎治疗药物的耐受问题,其对急性肾炎的治疗效果不因治疗时间延长而下降。
Description
技术领域
本发明涉及中药领域,具体涉及一种防治急性肾炎的药物组合物及其应用。
背景技术
急性肾小球肾炎简称急性肾炎,急性肾炎是一种由于感染后变态反应引起的两侧肾脏弥漫性肾小球损害为主的急性疾病,本病的特点是起病较急,在感染后1-3周出现血尿、蛋白尿、管型尿、水肿、少尿、高血压等系列临床表现。
肾炎是原发于肾小球的疾病。临床上有急性和慢性两种,急性肾炎多见于儿童,常发生于感染后,尤以溶血性链球菌“致肾炎菌株”感染后多见;起病急、病程短,主要表现为血尿、蛋白尿、少尿、水肿、高血压及氮质血症,积极治疗愈后较好,少数可发展为慢性肾炎。肾炎在祖国属中医“水肿”范畴,部分病例“水肿”不明显,而以血尿为主,则属血证中的“尿血”范畴。按急性肾炎水肿的特点,可归属风水、阳水类,其发病与风邪外袭,风水相后搏,或饮食不节,水湿浸渍,或房劳过度,阴虚邪淫有关,上述致病因素可单独致病,也可兼杂为病,但不离风、湿、毒三因,涉及肺、脾、肾三脏,当风湿毒邪伤及肺脾肾三脏,使肺失通调,脾失转输,肾失开合,三焦水道失畅,膀胱气化无权,而致水湿,毒邪内侵,水谷精微大量流失,而出现临床诸症。
急性肾小球肾的的病理改变是肾脏体积可较正常增大,病变主要累及肾小球。以内皮细胞及系膜细胞增生为主要表现,急性期可伴有中性粒细胞和单核细胞浸润。病变严重时,增生和浸润的细胞可压迫毛细血管袢使毛细血管腔变窄、甚至闭塞,并损害肾小球滤过膜,可出现血尿、蛋白尿及管型尿等;并使肾小球滤过率下降,发生水钠潴留,因此临床上有水肿、尿少、全身循环充血状态如呼吸困难、肝大、静脉压增高等。
急性肾小球肾炎治疗:
1、西药治疗首选青霉素800万单位静脉滴注,10-14天,但其必需性现有争议。对症治疗时,针对利尿、消肿、降血压,常用噻嗪类利尿剂,如双氢氯噻嗪。利尿后高血压值仍不满意时,可加用钙通道阻滞剂如硝苯啶20-40mg/d,分次口服或血管扩张药如肼酞嗪25mg,每日3次。但保钾利尿药(如氨苯蝶啶及安体舒通)及血管紧张素转化酶抑制剂,少尿时应慎用,以防诱发高血钾。
2、中医药治疗:中医中药治疗副作用小,注重肾脏的修复和保护,还具有标本兼治的效果。本病多属实证。根据辨证可分为风寒、风热、湿热,分别予以宣肺利尿,凉血解毒等疗法。本病恢复期脉证表现不很明确,辨证不易掌握,仍以清热利湿为主,佐以养阴,但不可温补。风热型:发热不恶寒、咽喉肿痛,面部轻度浮肿,舌苔薄黄,尿短赤涩,可见肉眼血尿;治则疏风清热,凉血解毒。湿热型:可有发热、唇干口苦、舌苔黄、脉滑数、尿少色红、头面或全身浮肿;治则清热利湿或清热解毒。风寒型:发病急,恶寒、发热、咳嗽、头面浮肿、尿少、血压高、舌苔薄白、脉浮紧;治则宣肺利水。
目前,治疗急性肾炎的西药很多,但大多数药物治疗效果差,并且还有治疗成本高、副作用大等缺点,严重时甚至影响患者健康。抗生素对急性肾炎的治疗效果较好,但抗生素的长期使用可以导致人体产生抗生素耐药性,且其使用会破坏肠道菌群的平衡,给患者的身心健康造成了严重的影响。另外,还有很多治疗急性肾炎的中药,但大多数具有治疗效果差、治愈率低和治疗周期长等缺点。本发明目的即在于提供一种作用全面,临床效果好的治疗急性肾炎的中药组合物。
纵观世界新药的研究方向,80年代以前主要是研究开发单一的化学药物及其制剂,80年代以后开始发展生物技术和天然植物药物,药物研究方向趋于多样性。结合现代中医药发展理论,从提高药物疗效、降低副作用的角度出发,经过对中药成分进行筛选提取和/或配伍制得的制剂,其副作用小,安全性高,具有化学合成药不能比拟的优势。
发明内容
本发明针对现有技术中的不足之处,提供一种防治急性肾炎的药物组合物及其应用,该药物组合物疗效好,副作用小。
本发明的上述目的是通过下述技术方案来实现的:
一种防治急性肾炎的药物组合物,制成所述药物组合物的原料组成及重量份数为:麻黄8-13份,金银花13-20份,蒲公英17-30份,茜根14-27份,仙鹤草17-23份,蝉蜕5-11份,重楼13-19份,夏枯草6-12份,泽泻3-9份,蛇床子11-16份,川芎14-25份,白芷8-18份,白芍19-30份,大蓟18-32份,桂枝13-24份,木通4-9份,知母9-15份,煅龙骨8-12份,防己7-12份,鹿角13-28份,山茱萸14-29份,茯苓皮12-21份,板蓝根6-13份。
进一步地,制成所述药物组合物的原料组成及重量份数为:麻黄8份,金银花13份,蒲公英17份,茜根14份,仙鹤草17份,蝉蜕5份,重楼13份,夏枯草6份,泽泻3份,蛇床子11份,川芎14份,白芷8份,白芍19份,大蓟18份,桂枝13份,木通4份,知母9份,煅龙骨8份,防己7份,鹿角13份,山茱萸14份,茯苓皮12份,板蓝根6份。
进一步地,制成所述药物组合物的原料组成及重量份数为:麻黄10份,金银花17份,蒲公英27份,茜根20份,仙鹤草23份,蝉蜕9份,重楼16份,夏枯草12份,泽泻5份,蛇床子15份,川芎15份,白芷13份,白芍30份,大蓟29份,桂枝22份,木通9份,知母15份,煅龙骨112份,防己12份,鹿角26份,山茱萸19份,茯苓皮21份,板蓝根13份。
进一步地,制成所述药物组合物的原料组成及重量份数为:麻黄13份,金银花20份,蒲公英30份,茜根24份,仙鹤草23份,蝉蜕11份,重楼13份,夏枯草11份,泽泻7份,蛇床子11份,川芎15份,白芷18份,白芍30份,大蓟22份,桂枝24份,木通9份,知母15份,煅龙骨10份,防己10份,鹿角28份,山茱萸29份,茯苓皮21份,板蓝根13份。
进一步地,制成所述药物组合物的原料组成及重量份数为:麻黄11份,金银花18份,蒲公英27份,茜根21份,仙鹤草20份,蝉蜕10份,重楼15份,夏枯草11份,泽泻8份,蛇床子16份,川芎25份,白芷18份,白芍30份,大蓟28份,桂枝24份,木通9份,知母15份,煅龙骨11份,防己10份,鹿角27份,山茱萸28份,茯苓皮18份,板蓝根12份。
进一步地,制成所述药物组合物的原料组成及重量份数为:麻黄9份,金银花12份,蒲公英21份,茜根20份,仙鹤草18份,蝉蜕6份,重楼13份,夏枯草7份,泽泻4份,蛇床子14份,川芎23份,白芷16份,白芍29份,大蓟31份,桂枝23份,木通5份,知母13份,煅龙骨9份,防己8份,鹿角15份,山茱萸28份,茯苓皮19份,板蓝根6份。
进一步地,制成所述药物组合物的原料组成及重量份数为:麻黄13份,金银花13份,蒲公英17份,茜根17份,仙鹤草23份,蝉蜕11份,重楼13份,夏枯草12份,泽泻3份,蛇床子16份,川芎14份,白芷18份,白芍30份,大蓟18份,桂枝13份,木通9份,知母15份,煅龙骨8份,防己7份,鹿角13份,山茱萸19份,茯苓皮21份,板蓝根6份。
本发明还涉及一种药物组合物的应用,所述药物组合物制成糖浆剂、汤剂、散剂、膏剂、片剂、胶囊或颗粒剂。
以下是本发明药物组合物的药材来源及主要功效:
麻黄:麻黄科植物草麻黄Ephedra sinica Stapf、中麻黄Ephedra intermedia Schrenket C.A.Mey.或木贼麻黄Ephedra equisetina Bge.的干燥草质茎。发汗解表和利水消肿力强,多用于风寒表实证,胸闷喘咳,风水浮肿,风湿痹痛,阴疽,痰核。
金银花:忍冬科植物忍冬Lonicera japonica Thunb.、红腺忍冬Lonicera hypoglaucaMiq.、山银花Lonicera confusa DC.或毛花柱忍冬Lonicera dasystyla Rehd.的干燥花蕾或带初开的花。性甘寒气芳香,甘寒清热而不伤胃,芳香透达又可祛邪。金银花既能宣散风热,还善清解血毒,用于各种热性病,如身热、发疹、发斑、热毒疮痈、咽喉肿痛等证,均效果显著。
蒲公英:为菊科植物蒲公英Taraxacum mongolicum Hand.-Mazz.、碱地蒲公英Taraxacumsinicum Kitag.或同属数种植物的干燥全草。清热解毒,消肿散结,利尿通淋。用于疔疮肿毒,乳痈,瘰疠,目赤,咽痛,肺痈,肠痈,湿热黄疸,热淋涩痛。
茜根:为茜草科植物茜草Rubia cordifolia L.的干燥根及根茎。味苦寒。主寒湿,风痹,黄疽,补中。
仙鹤草,蔷薇科植物龙芽草Agrimonia pilosa Ledeb.的干燥地上部分。又名西洋龙芽。扶正力宏而不留邪。能收敛止血,解毒疗疮,杀虫,涩汗,止咳。
蝉蜕:味甘;咸;性凉。入肺;肝经。宣散风热;透疹利咽;退翳明目;祛风止痉。主治风热感冒;咽喉肿痛;咳嗽音哑;顽疹不透;风疹瘙痒;目赤翳障;惊痫抽搐;破伤风。《纲目》载:“治头风眩运,皮肤风热,痘疹作痒,破伤风及疗肿毒瘤,大人失音,小儿噤风天吊,惊哭夜啼,阴肿。”现代医学研究证实,蝉蜕具有明显的抗惊厥、镇静作用,能阻断颈上副交感神经的传导,广泛应用于治疗破伤风、慢性荨麻诊、化脓性中耳炎、血管神经性水肿,此外还有止咳嗽,特别是喉痒之咳的作用。
重楼:性微寒,味苦;有小毒。入肝经。清热解毒,消肿止痛,凉肝定惊。作于疔肿痈肿、咽喉肿痛、毒蛇咬伤、跌扑伤痛、惊风抽搐。《本草纲目》载:“蛇虫之毒,得此治之即休,故有蚤休、螫休诸名。重台、三层,因其叶状也。”
夏枯草:味苦;辛;性寒。归肝;胆经。清肝明目;散结解毒。主治目翳羞明;目珠疼痛;头痛眩晕;耳鸣;瘰疬;瘿瘤;乳痈;痄腮;痈疖肿毒;急慢性肝炎;高血压病。《滇南本草》载:“祛肝风,行经络。治口眼歪斜,行肝气,开肝郁,止筋骨疼痛,目珠痛,散瘰疬,周身结核。”现代医学研究证实,夏枯草具有显著的降压和抗菌作用。
泽泻为泽泻科植物泽泻的块茎。中医理论认为其性寒,具有利水渗湿的功效。现代医学研究,泽泻可降低血清总胆固醇及三酰甘油含量,减缓动脉粥样硬化形成;泽泻及其制剂现代还用于治疗内耳眩晕症、血脂异常、遗精、脂肪肝及糖尿病等。但泽泻具有肝毒性、肾毒性,服用不当,能让肝脏、肾脏出现肿胀以及其他中毒症状。
蛇床子为伞形科植物蛇床的果实。别名:蛇米、蛇珠、蛇粟、蛇床仁、蛇床实、气果、双肾子、癞头花子、野茴香。有温肾壮阳;燥湿杀虫;祛风止痒的功效。治男子阳痿;阴囊湿痒;女子宫寒不孕;寒湿带下;阴痒肿痛;风湿痹痛;湿疮疥癣。唐代用于阳痿及宫冷不孕。蛇床子有温肾助阳之功,治疗肾阴虚衰引起的男子阳痿,女子宫冷不孕,可与枸杞子、菟丝子、五味子、肉桂等同用,以益肾补火,助阳兴痿;《千金方》治肾阳虚寒,阳痿不起的天雄丸,即以本品配伍而成。用于男子阴囊湿痒,女子阴痒带下,湿疹疥癣。蛇床子可燥湿祛风,杀虫止痒。治阴囊湿疹,女子阴痒带多,可单用或与苦参、黄柏、明矾等煎汤外洗。
川芎辛温香燥,走而不守,既能行散,上行可达巅顶;又入血分,下行可达血海。活血祛瘀作用广泛,适宜瘀血阻滞各种病症;祛风止痛,效用甚佳,可治头风头痛、风湿痹痛等症。昔人谓川芎为血中之气药,殆言其寓辛散、解郁、通达、止痛等功能。本品辛温升散,凡阴虚阳亢及肝阳上亢者不宜应用;月经过多、孕妇亦忌用。
白芷,性温,味辛微甘,具有祛风除湿;通窃止痛;消肿排脓的功效。主感冒头痛;眉棱骨痛;牙痛;鼻塞;鼻渊;湿胜久泻;妇女白带;痈疽疮疡;毒蛇咬伤。临床用于感冒头痛,眉棱骨痛,鼻塞,鼻渊,牙痛,白带,疮疡肿痛。也可用于解表散寒,祛风止痛,通鼻窍,燥湿止带,消肿排脓。治头痛,眉棱骨痛,齿痛,鼻渊,寒湿腹痛,肠风痔漏,赤白带下,痈疽疮疡,皮肤燥痒,疥癣。苍术具有燥湿健脾,祛风散寒,明目的功效,用于湿阻脾胃、脘腹胀满,寒湿白带,湿温病以及湿热下注、脚膝肿痛、痿软无力。治湿阻脾胃,而见脘腹胀满、食欲不振、倦怠乏力、舌苔白腻厚浊等症,常与厚朴、陈皮等配伍应用。
白芍为我国著名的传统常用中药材,应用历史悠久,芍药始载于东汉《神农本草经》,列为中品,记有“主邪气,白芍腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便,益气”。养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下等症。现代药理学研究显示,芍药甙对豚鼠、大鼠的离体肠管和在胃运动,以及大鼠子宫平滑机均表现抑制,并能拮抗催产素所引起的收缩;用醋酸注射于小鼠腹腔,以扭体反应作为疼痛的指标,芍药甙有显著的镇痛效果;芍药的浸膏能拮抗士的宁所引起的惊厥;白芍煎剂在试管内对志贺氏痢疾杆菌有抑菌作用,浸剂对某些致病性真菌亦有抑制作用。芍药甙对小白鼠正常体温有降温作用,对人工发热的小鼠也有解热作用。对大鼠实验性后足跖浮肿有抗炎作用;芍药甙在试管内或静脉注射时对二磷酸腺苷诱导的大鼠血小板聚集有抑制作用;芍药甙对由于紧张刺激而诱发的大鼠消化道溃疡有明显的抑制作用。
大蓟主要成分含生物碱、挥发油、乙酸蒲公英甾醇、豆甾醇、a一香树脂醇、B-蓟香树脂醇、B-谷甾醇、柳穿鱼花甙2-1%,味甘,苦,性凉,无毒,归心、肝经,具有凉血、止血、消痛、解毒的功效,治吐血、衄血、尿血、血淋、血崩、肠风、肠痈、痈疡肿毒、疔疮等病症。
桂枝味辛甘,性温,是里寒常用的内温药,具有补元阳、通腑降浊、通血脉、暖脾胃之功效,常与补肝肾药、补气血药配伍,治疗肾阳不足、命门火衰、肢冷脉微,与其它温里药配伍治疗脘腹冷痛、寒痹腰痛,具有明显的镇痛和抗癌防癌的作用。
木通味苦,性微寒,归脾、心、小肠、肾、膀胱经,具有清热、利尿、活血、通脉、泄浊、排毒等功效,治小便赤赤、淋浊、水肿、胸中烦热、风湿痹痛、乳汁不通、闭经、痛经等病症。
知母属于清热、下火药,味苦,性寒,归肺、胃、肾经,有滋阴降火、润燥滑肠、利尿、清热泻火之效,用于温病、阴虚燥咳、肠燥便秘、阴虚火旺、骨蒸潮热、清泄肺胃之火、滋养肺肾之阴等症状。
煅龙骨含羟磷酸钙Ca5(PO4)3(OH)(羟磷灰石);尚含少量碳酸钙CaCO3(方解石)及铁、铝、镁、锰、锶等元素,味甘,性寒,归心、肝、肾、大肠经,具有镇惊安神、敛汗固精、止血涩肠、生肌敛疮的作用,用于治疗惊痫癫狂、怔忡健忘、失眠多梦、自汗盗汗、遗精淋浊、吐衄便血、崩漏带下、泻痢脱肛等。
防己:苦,寒。归膀胱、肺经。利水消肿,祛风止痛。用于水肿脚气,小便不利,湿疹疮毒,风湿痹痛;高血压。
鹿角:行血,消肿,益肾。治疮疡肿毒,瘀血作痛,虚劳内伤,腰脊疼痛。
山茱萸:补肝肾,涩精气,固虚脱。治腰膝酸痛,眩晕,耳鸣,阳痿,遗精,小便频数,肝虚寒热,虚汗不止,心摇脉散。
茯苓皮:性味归经:平;甘、淡;归心、肺、脾、肾经。功能主治:利水渗湿,健脾宁心。用于水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。
板蓝根:清热,解毒,凉血,利咽。桑白皮:性味归经:寒;甘;归肺经。功能主治:泻肺平喘,利水消肿。用于肺热喘咳,水肿胀满尿少,面目肌肤浮肿。甘草:味甘,性平。归心、肺、脾、胃经。有益气补中,清热解毒,祛痰止咳,缓急止痛,缓和药性之功效。
本发明提供的防治急性肾炎的药物组合物具有以下优点:
(1)与常用西药相比,本发明药物组合物中药物成分不仅在抗炎和镇痛方面更为显著,而且在活血化淤方面也显著优于阳性药物,这表明本发明药物组合物在急性肾炎治疗中具有显著的协同作用,不仅能够显著改善急性肾炎的症状,还能延缓急性肾炎的发展,有助于急性肾炎患者的痊愈过程;
(2)该药物组合物为天然纯中药制剂,不良反应和副作用显著降低,特另是其对于肠道黏膜不产生任何破坏作用,且该药物组合物作用全面,药物治疗效果更佳,显著提高了急性肾炎患者的用药依从性,并提高了患者的生活质量;
(3)现有医学上使用的抗生素药物在急性肾炎初期治疗效果尚可,但随着治疗时间的延长均出现明显的药物耐受问题,其对于急性肾炎的治疗效果下降;本发明药物组合物中含有多种药物组分,作用靶点众多,有效地解决了急性肾炎治疗药物的耐受问题,其对急性肾炎的治疗效果不因治疗时间延长而下降。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合实施例对本发明的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明的一部分,而不是全部的实施例。基于所描述的本发明的实施例,本领域普通技术人员在无需创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。除非另有说明,本发明中的乙醇量的百分数是体积百分数,v/v表示溶液的体积比。
实施例1:
本发明的一种防治急性肾炎的药物组合物,取下列中药原料药:麻黄8克,金银花13克,蒲公英17克,茜根14克,仙鹤草17克,蝉蜕5克,重楼13克,夏枯草6克,泽泻3克,蛇床子11克,川芎14克,白芷8克,白芍19克,大蓟18克,桂枝13克,木通4克,知母9克,煅龙骨8克,防己7克,鹿角13克,山茱萸14克,茯苓皮12克,板蓝根6克。
所述防治急性肾炎的药物组合物的制各方法为:
(1)取组合物中各药材,按照常规工艺研磨成粉状,过100目筛,小火烘干备用。
(2)加入乙醇渗漉提取4次,每次加入乙醇量分别相当于药材总重量2倍、2倍、1倍、1倍,四次渗漉用乙醇浓度分别为60%、50%、40%、40%,四次渗滤速度分别为每分钟流出液约占原料总重量的0.2%、0.3%、0.4%、0.6%,收集渗滤液,回收乙醇,减压浓缩至相当于药材总重量的1倍,滤过,加入甘油、尼泊金、甜菊糖,混匀,分装,即得糖浆剂。
临床资料:
病例:2007年6月,黄某,男9岁,就诊前5天前咽喉肿痛,继而发热,体温38-39℃,经门诊静脉滴注青霉素等治疗,体温有所下降,3天前渐见面容浮肿,头痛乏力,食欲不振,恶心欲呕,尿黄短赤。舌淡红、苔薄黄、脉数。尿检:蛋白++,红细胞+++,颗粒管型+。血压140/80mmHg。西医诊断:急性肾小球肾炎。中医辩证:水肿,证属湿热蕴结,治以清热解毒、活血化瘀、利水渗湿。服用本发明实施例3糖浆剂,每次10ml,每日3次,服用3天后,尿量明显增多,体温降至正常。连服7天后,浮肿尽退,咽痛亦除,舌淡红、苔薄白。随访3月,未见复发,诸症悉除,尿检正常。
实施例2:
本发明的一种防治急性肾炎的药物组合物,取下列中药原料药:麻黄10克,金银花17克,蒲公英27克,茜根20克,仙鹤草23克,蝉蜕9克,重楼16克,夏枯草12克,泽泻5克,蛇床子15克,川芎15克,白芷13克,白芍30克,大蓟29克,桂枝22克,木通9克,知母15克,煅龙骨112克,防己12克,鹿角26克,山茱萸19克,茯苓皮21克,板蓝根13克。
所述防治急性肾炎的药物组合物的制备方法具体为以下步骤:
(1)按上述配比提取各中药原料药,然后共同细研成药末,备用;
(2)取步骤(1)中研磨的药末放置于砂锅中加水,水量为药末重量的5倍,然后用大火将水煮沸6-7min后,改小火煎熬,煎熬时搅拌药末,搅拌次数为2-3次,煎熬时间为30-45min,煎熬完成后滤去药渣,取药液。
临床资料:
病例:2009年1月,刘某,男,59岁,因常年高血压、关节炎等疾病胡乱吃药,引起了药物性肾损伤,经医院检查,左肾肾小球已经基本无滤过功能,右肾肾小球滤过功能中度受损,在医院做了两次血液透析,病情无明显好转,服用本发明所述的药液一个疗程之后,症状基本消失,继续服用两个疗程后,生活恢复正常,未复发。
实施例3:
本发明的一种防治急性肾炎的药物组合物,取下列中药原料药:麻黄13克,金银花20克,蒲公英30克,茜根24克,仙鹤草23克,蝉蜕11克,重楼13克,夏枯草11克,泽泻7克,蛇床子11克,川芎15克,白芷18克,白芍30克,大蓟22克,桂枝24克,木通9克,知母15克,煅龙骨10克,防己10克,鹿角28克,山茱萸29克,茯苓皮21克,板蓝根13克。
所述防治急性肾炎的药物组合物的制备方法具体为以下步骤:
(1)按上述配比提取各中药原料药,然后共同细研成药末,备用;
(2)用40%乙醇回流提取3次,每次乙醇用量分别为药材总量的10倍、8倍、4倍,提取时间分别4小时、2小时、1小时,合并提取液,过滤,滤液浓缩至60℃时相对密度为1.25的浸膏,即得活性成分,加入乳糖、淀粉、制粒、干燥、整粒,分装,即得颗粒剂。
临床资料:
病例:2011年11月,杨某,男,42岁。患者半年前发现腰部酸痛、双下肢水肿,平常工作压力大,生活不规律,伴有间歇性镜下血尿,去医院检查诊断为急性肾炎。半年来多方治疗,效果不明显。经服用本发明药物颗粒剂治疗三个疗程后,患者尿检查转阴,各项指标回复正常,康复出院,定期复诊。
实施例4:
本发明的一种防治急性肾炎的药物组合物,取下列中药原料药:麻黄11克,金银花18克,蒲公英27克,茜根21克,仙鹤草20克,蝉蜕10克,重楼15克,夏枯草11克,泽泻8克,蛇床子16克,川芎25克,白芷18克,白芍30克,大蓟28克,桂枝24克,木通9克,知母15克,煅龙骨11克,防己10克,鹿角27克,山茱萸28克,茯苓皮18克,板蓝根12克。
上述药物组合物的制备方法,步骤是:
取上述各中药原料药,加水提取2次,每次加水量分别相当于药材总重量的12倍、10倍,每次提取时间分别为3小时、2小时,合并提取液,滤过,滤液浓缩至80℃下相对密度为1.05的清膏,加入乙醇,使含醇量为70%,静置12小时,滤过,滤液浓缩至70℃时相对密度为1.25的浸膏,加入糊精、硬脂酸镁、微晶纤维素,混匀,制粒、干燥、压片,即得片剂。临床资料:
病例:2013年10月,葛某,女6岁,就诊前2天前头面部浮肿,头痛发热,咽喉肿痛,咳嗽,口渴多饮,尿少赤涩,体温38-39℃。尿检:蛋白++,红细胞+++,颗粒管型+。中医辩正:风热型急性肾炎。服用本发明药物组合物片剂,每次10g,每目3次,服用3天后,咽痛明显减轻,尿量明显增多,体温降至正常。连服10天后,浮肿尽退,咽痛亦除,诸症皆除,尿检正常。
实施例5:
本发明的一种防治急性肾炎的药物组合物,取下列中药原料药:麻黄9克,金银花12克,蒲公英21克,茜根20克,仙鹤草18克,蝉蜕6克,重楼13克,夏枯草7克,泽泻4克,蛇床子14克,川芎23克,白芷16克,白芍29克,大蓟31克,桂枝23克,木通5克,知母13克,煅龙骨9克,防己8克,鹿角15克,山茱萸28克,茯苓皮19克,板蓝根6克。
上述药物组合物的制备方法,步骤是:按上述配比提取各中药原料药,加入乙醇渗滤提取3次,每次加入乙醇量相当于药材总重量2倍、2倍、1倍,三次渗滤用乙醇浓度分别为60%、50%、40%,渗滤速度为每分钟流出液约占原料总重量0.2%~0.6%,收集渗滤液,回收乙醇,减压浓缩至相当于药材总重量的2倍,滤过,加入聚乙二醇、淀粉、滑石粉,混匀、制粒、干燥、过筛,入胶囊,即得胶囊剂。
临床资料:
病例:2009年12月,谢某,女,13岁。3天前出现浮肿、尿少、腰酸痛等症状,血压110/90mmHg,舌淡红,苔薄白,脉浮紧。尿检:尿蛋白(+++),红细胞+++,颗粒管型+。证属内蕴毒热,肺失宣降。服用本发明实施例6片剂,每次3片,每日3次,服用2次后,尿量明显增多,浮肿渐退,腰酸痛症状减轻。连服7天后,浮肿消退,再查尿蛋白阴性,沉渣中有极少数红血球,连服14天,浮肿消失,血压正常,尿常规化验正常。
实施例6
一种防治急性肾炎的药物组合物,取下列中药原料药:麻黄13克,金银花13克,蒲公英17克,茜根17克,仙鹤草23克,蝉蜕11克,重楼13克,夏枯草12克,泽泻3克,蛇床子16克,川芎14克,白芷18克,白芍30克,大蓟18克,桂枝13克,木通9克,知母15克,煅龙骨8克,防己7克,鹿角13克,山茱萸19克,茯苓皮21克,板蓝根6克。
上述药物组合物的制备方法,步骤是:按照常规工艺研磨成粉状,过100目筛,小火烘干备用,制成散剂。使用时,用水溶解后直接冲服。
临床资料:
病例:2012年1月,安某,女,63岁,一次感冒引起了恶心、呕吐、全身乏力等症状,经医院诊断为急性肾功能衰竭,医院两个月的治疗,症状减轻,但病无好转,服用本发明所述的药物一个疗程后,症状基本消失,继续服用一个疗程后痊愈。
临床论证:
为了验证本发明中药组合物的效果,2012年6月-2013年9月,在齐鲁医院多名泌尿科专家的指导下,随机选择急性肾炎患者200例,其中男性95例,女性105例;年龄15-71岁,平均(36±5)岁;均有腹痛、发热,腹痛位于右上腹部或剑突下并伴有恶心、呕吐者174例,体温37.5-38.9℃者132例;出现黄疸者105例,中性白细胞升高者158例。按随机数字表法分为治疗组与对照组各100例。两组患者性别、年龄、症状等差异无显著性(P>0.05),具有可比性。
1、病例选择:选择已确诊的急性肾炎患者200例临床观察,病人随机分成两组。治疗组100例,其中儿童57例,年龄在3-7岁,成人43例,年龄在27-51岁。对照组100例,儿童55例,年龄在4-8岁,成人45例,年龄在31-53岁。两组资历基本一致,无显著差异,具有可比性。
2、治疗过程治疗组患者服用本发明药物,选择片剂,治疗组每日3次,成人每次3片,儿童每次1片,症状严重者,每日3次,每次4片,7天为一个疗程,3-6个月内完全恢复。对照组根据诊断出的急性肾炎,分别予以肌注青酶素或其他有效抗生素,严重者静注速尿和安定,静滴硝普钠、酚妥拉明等治疗手段,10天为一个疗程,5-12个月内才逐渐消失,少数病例1-2年后逐渐康复。
疗效判断标准:①临床治愈:水肿、尿少、血尿、高血压等症状全消失,实验室检查各项指标均正常;②显效:水肿、尿少、血尿、高血压等症状显著减轻,各项实验室正常或仅一项稍高于正常值;③有效:水肿、尿少、血尿、高血压等症状改善,血清尿素氮、肌酐清除率稳定,尿常规在正常范围值;④无效:症状、体征未见明显改善,甚至恶化或转手术治疗。
我们对实验数据进行了精确的统计和数理分析。具体实验结果如下表:
表1:三组临床疗效比较
| 组别 | 病例数 | 治愈 | 显效 | 有效 | 无效 | 总有效率 |
| 对照组 | 100 | 85 | 8 | 5 | 2 | 98% |
| 实验组 | 100 | 47 | 12 | 11 | 30 | 70% |
表2:急性肾炎患者治疗前后的白细胞数目
| 组别 | 病例数 | 治疗前白细胞数×109 | 治疗后白细胞数×109 |
| 实验组 | 100 | 10.65±1.25 | 6.65±0.86 |
| 对照组 | 100 | 10.75±1.33 | 8.92±0.98 |
结果:经临床疗效比较,对照组总有效率为70%;实验组总有效率分别为98%,两组总有效率比较表明实验组疗效优于对照组。
综上所述,本发明药物组合物与其它防治急性肾炎的药物相比有效率高,总有效率为98%,比对照组有效率高28%,效果明显优于对照组,该发明的药物组合物造价低廉,普通百姓长期使用,也不会增加身体和金钱上的负担。临床实验中未出现一例副作用情况,安全性远高于防治急性肾炎的同类药物,且疗效显著,使用本发明中药组合物能够快速缓解疾病的附加症状,而且能调理因病而致虚弱的身体,属于标本兼顾的组方,是目前防治急性肾炎较为理想安全的中药组合物。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (8)
1.一种防治急性肾炎的药物组合物,其特征在于,制成所述药物组合物的原料组成及重量份数为:麻黄8-13份,金银花13-20份,蒲公英17-30份,茜根14-27份,仙鹤草17-23份,蝉蜕5-11份,重楼13-19份,夏枯草6-12份,泽泻3-9份,蛇床子11-16份,川芎14-25份,白芷8-18份,白芍19-30份,大蓟18-32份,桂枝13-24份,木通4-9份,知母9-15份,煅龙骨8-12份,防己7-12份,鹿角13-28份,山茱萸14-29份,茯苓皮12-21份,板蓝根6-13份。
2.根据权利要求1所述的防治急性肾炎的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:麻黄8份,金银花13份,蒲公英17份,茜根14份,仙鹤革17份,蝉蜕5份,重楼13份,夏枯草6份,泽泻3份,蛇床子11份,川芎14份,白芷8份,白芍19份,大蓟18份,桂枝13份,木通4份,知母9份,煅龙骨8份,防己7份,鹿角13份,山茱萸14份,茯苓皮12份,板蓝根6份。
3.根据权利要求1所述的防治急性肾炎的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:麻黄10份,金银花17份,蒲公英27份,茜根20份,仙鹤草23份,蝉蜕9份,重楼16份,夏枯草12份,泽泻5份,蛇床子15份,川芎15份,白芷13份,白芍30份,大蓟29份,桂枝22份,木通9份,知母15份,煅龙骨112份,防己12份,鹿角26份,山茱萸19份,茯苓皮21份,板蓝根13份。
4.根据权利要求1所述的防治急性肾炎的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:麻黄13份,金银花20份,蒲公英30份,茜根24份,仙鹤草23份,蝉蜕11份,重楼13份,夏枯草11份,泽泻7份,蛇床子11份,川芎15份,白芷18份,白芍30份,大蓟22份,桂枝24份,木通9份,知母15份,煅龙骨10份,防己10份,鹿角28份,山茱萸29份,茯苓皮21份,板蓝根13份。
5.根据权利要求1所述的防治急性肾炎的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:麻黄11份,金银花18份,蒲公英27份,茜根21份,仙鹤草20份,蝉蜕10份,重楼15份,夏枯草11份,泽泻8份,蛇床子16份,川芎25份,白芷18份,白芍30份,大蓟28份,桂枝24份,木通9份,知母15份,煅龙骨11份,防己10份,鹿角27份,山茱萸28份,茯苓皮18份,板蓝根12份。
6.根据权利要求1所述的防治急性肾炎的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:麻黄9份,金银花12份,蒲公英21份,茜根20份,仙鹤草18份,蝉蜕6份,重楼13份,夏枯草7份,泽泻4份,蛇床子14份,川芎23份,白芷16份,白芍29份,大蓟31份,桂枝23份,木通5份,知母13份,煅龙骨9份,防己8份,鹿角15份,山茱萸28份,茯苓皮19份,板蓝根6份。
7.根据权利要求1所述的防治急性肾炎的药物组合物,其特征在于:制成所述药物组合物的原料组成及重量份数为:麻黄13份,金银花13份,蒲公英17份,茜根17份,仙鹤草23份,蝉蜕11份,重楼13份,夏枯草12份,泽泻3份,蛇床子16份,川芎14份,白芷18份,白芍30份,大蓟18份,桂枝13份,木通9份,知母15份,煅龙骨8份,防己7份,鹿角13份,山茱萸19份,茯苓皮21份,板蓝根6份。
8.根据权利要求1-7任一所述的药物组合物的应用,其特征在于:所述药物组合物制成糖浆剂、汤剂、散剂、膏剂、片剂、胶囊或颗粒剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410809891.5A CN104524149A (zh) | 2014-12-24 | 2014-12-24 | 一种防治急性肾炎的药物组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410809891.5A CN104524149A (zh) | 2014-12-24 | 2014-12-24 | 一种防治急性肾炎的药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104524149A true CN104524149A (zh) | 2015-04-22 |
Family
ID=52839905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410809891.5A Pending CN104524149A (zh) | 2014-12-24 | 2014-12-24 | 一种防治急性肾炎的药物组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104524149A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106620356A (zh) * | 2017-02-16 | 2017-05-10 | 姜青春 | 一种用于护理治疗急性肾炎的中药组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089482A (zh) * | 1993-01-14 | 1994-07-20 | 楼佩文 | 肾炎康 |
| CN1136926A (zh) * | 1995-05-30 | 1996-12-04 | 吴常庆 | 一种治疗急慢性肾炎病的中药 |
-
2014
- 2014-12-24 CN CN201410809891.5A patent/CN104524149A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089482A (zh) * | 1993-01-14 | 1994-07-20 | 楼佩文 | 肾炎康 |
| CN1136926A (zh) * | 1995-05-30 | 1996-12-04 | 吴常庆 | 一种治疗急慢性肾炎病的中药 |
Non-Patent Citations (4)
| Title |
|---|
| 何伦等: "麻黄汤类方鉴别运用", 《陕西中医》 * |
| 姜润林: "商陆麻黄汤治疗小儿急性肾炎68例", 《辽宁中医杂志》 * |
| 李永来: "《中华名方》", 30 November 2008, 线装书局 * |
| 毛伟松等: "小儿急性肾炎的中医药治疗进展", 《现代中西医结合杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106620356A (zh) * | 2017-02-16 | 2017-05-10 | 姜青春 | 一种用于护理治疗急性肾炎的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN106267120A (zh) | 一种治疗鼻炎的中药制剂及其制备方法 | |
| CN103432559A (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
| CN102302733B (zh) | 治疗卵巢囊肿的内服中药组合物 | |
| CN104491236A (zh) | 一种治疗原发性高血压的中药制剂及其制备方法 | |
| CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
| CN106334171A (zh) | 一种用于修复肝损伤的中药制剂及制备方法 | |
| CN104771578A (zh) | 用于治疗变应性鼻炎的中药 | |
| CN105381410A (zh) | 一种治疗肝炎的中药制剂 | |
| CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
| CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
| CN105435131A (zh) | 一种治疗慢性心衰的中药组合物及其制备方法 | |
| CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
| CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
| CN104958677A (zh) | 一种治疗膜性肾病的中药制剂及其制备方法 | |
| CN104524460A (zh) | 一种防治急性肾炎的药物组合物及其应用 | |
| CN104771585A (zh) | 一种治疗急性肾炎的中药组合物及制备方法 | |
| CN104147573A (zh) | 治疗风感头痛的清热解毒制剂及制法 | |
| CN104740405B (zh) | 一种治疗过敏性紫癜性肾损害的中药制剂及制备方法 | |
| CN103330896B (zh) | 一种治疗产后非特异性阴道炎的散剂制备方法 | |
| CN106166251A (zh) | 一种用于治疗哮喘的中药制剂及其制备方法 | |
| CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
| CN106310018A (zh) | 一种预防和治疗湿疹的中药组合物及其制备方法 | |
| CN104688855A (zh) | 一种治疗慢性疲劳综合症的黄连阿胶组合物及其应用 | |
| CN104922595A (zh) | 一种用于带状疱疹的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |